Single Ascending Dose (SAD)/Multiple Ascending Dose(MAD) Safety/Pharmacokinetic (PK) Study of KM-023

NCT01348516 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

83

Enrollment

INDUSTRY

Sponsor class

Conditions

Human Immunodeficiency Virus

Interventions

DRUG: KM-023
DRUG: Placebo for KM-023

Sponsor

Kainos Medicine Inc.